We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Epistem Presents its new Ex Vivo Plucked Hair Biomarker Assay at EORTC-NCI-AACR Symposium
News

Epistem Presents its new Ex Vivo Plucked Hair Biomarker Assay at EORTC-NCI-AACR Symposium

Epistem Presents its new Ex Vivo Plucked Hair Biomarker Assay at EORTC-NCI-AACR Symposium
News

Epistem Presents its new Ex Vivo Plucked Hair Biomarker Assay at EORTC-NCI-AACR Symposium

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Epistem Presents its new Ex Vivo Plucked Hair Biomarker Assay at EORTC-NCI-AACR Symposium"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Epistem plc has announced presentation of its novel ex vivo plucked hair biomarker assay at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Berlin on Friday 19th November.

Epistem has developed a method for maintaining plucked human hairs ex vivo, and then treating with therapeutic agents to obtain valuable information on the cellular response to drug treatment.

Epistem senior scientist Dr Ben Jackson will present the model during the "Biomarkers" poster category (abstract # 648). The data demonstrate that freshly plucked hairs can be kept in short-term culture and that treatment-related changes in protein expression can be detected by immunohistochemistry and quantified by image analysis. This continues the expansion of Epistem's hair biomarker platform in which plucked hairs act as a surrogate biomarker tissue for monitoring the specific pharmacodynamic response of epithelial tissue to oncology agents.

The addition of this ex vivo assay permits the rapid treatment and analysis of hair, confirming its utility in biomarker programmes before commencing more costly clinical studies with patients.

Matthew Walls, Epistem CEO commented "Epistem are at the forefront of biomarker research and continue to invest in the development of innovative models to assist the drug development industry with their biomarker programmes. The new ex vivo assay further complements our growing portfolio of personalized medicine applications".
Advertisement